Zobrazeno 1 - 10
of 399
pro vyhledávání: '"Hideyasu, Matsuyama"'
Autor:
Makito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, Tatsuki Miyamoto, Tomonori Nakahama, Tomomi Fujii, Hiroaki Matsumoto, Hideyasu Matsuyama, Masaya Yonemori, Hideki Enokida, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Yoshiyuki Matsui, Naotaka Nishiyama, Hiroyuki Nishiyama, Kiyohide Fujimoto, Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group
Publikováno v:
BJUI Compass, Vol 5, Iss 2, Pp 269-280 (2024)
Abstract Objective The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the Eu
Externí odkaz:
https://doaj.org/article/9c82631e4e444a6c8093d7f9162013b7
Autor:
Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Takeshi Seto, Yoshinori Sunaga, Kazuhiro Suzuki
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background The CARD trial was conducted in patients with metastatic castration-resistant prostate cancer (mCRPC) who had received docetaxel and experienced disease progression within 1 year on an androgen receptor-axis-targeted therapy (ARAT
Externí odkaz:
https://doaj.org/article/432b9da7ab64418bb16272efd863cee6
Autor:
Makito Miyake, Nobutaka Nishimura, Tomonori Nakahama, Koshiro Nishimoto, Masafumi Oyama, Yuto Matsushita, Hideaki Miyake, Hideo Fukuhara, Keiji Inoue, Keita Kobayashi, Hiroaki Matsumoto, Hideyasu Matsuyama, Tomomi Fujii, Yoshihiko Hirao, Kiyohide Fujimoto
Publikováno v:
BJUI Compass, Vol 4, Iss 3, Pp 305-313 (2023)
Abstract Objectives The objective of this work is to evaluate the additional oncological benefit of photodynamic diagnosis (PDD) using blue‐light cystoscopy in transurethral resection (TURBT) for primary non‐muscle‐invasive bladder cancer (NMIB
Externí odkaz:
https://doaj.org/article/4723c0f9cce846d2942b2918f68143ef
Autor:
Kimihiko Nakamura, Naohito Isoyama, Yuki Nakayama, Toshiya Hiroyoshi, Koki Fujikawa, Yutaka Miura, Hiroshi Kurosu, Hideyasu Matsuyama, Makoto Kuro-o
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract Calciprotein particles (CPPs) are circulating colloidal mineral-protein complexes containing crystalline and/or non-crystalline (amorphous) calcium-phosphate (CaPi). Serum CPP levels correlate with vascular stiffness and calcification in pat
Externí odkaz:
https://doaj.org/article/fad24fc36bbc4644b0b2010bcae78329
Autor:
Makito Miyake, Kota Iida, Nobutaka Nishimura, Takashi Inoue, Hiroaki Matsumoto, Hideyasu Matsuyama, Yuya Fujiwara, Kazumasa Komura, Teruo Inamoto, Haruhito Azuma, Hiroaki Yasumoto, Hiroaki Shiina, Masaya Yonemori, Hideki Enokida, Masayuki Nakagawa, Hideo Fukuhara, Keiji Inoue, Takashi Yoshida, Hidefumi Kinoshita, Tadashi Matsuda, Tomomi Fujii, Kiyohide Fujimoto
Publikováno v:
European Urology Open Science, Vol 41, Iss , Pp 95-104 (2022)
Background: Site-specific postoperative risk models for localized upper tract urothelial carcinoma (UTUC) are unavailable. Objective: To create specific risk models for renal pelvic urothelial carcinoma (RPUC) and ureteral urothelial carcinoma (UUC),
Externí odkaz:
https://doaj.org/article/9e2f1052af52442ba6e77957eac8e055
Autor:
Hirotaka Kazama, Osamu Kawaguchi, Takeshi Seto, Kazuhiro Suzuki, Hideyasu Matsuyama, Nobuaki Matsubara, Yuki Tajima, Taro Fukao
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background We aimed to evaluate relationships between clinical outcomes and explanatory variables by network clustering analysis using data from a post marketing surveillance (PMS) study of castration-resistant prostate cancer (CRPC) patient
Externí odkaz:
https://doaj.org/article/77cc46ee50834c50b5247a2c826c7486
FKBP51 and FKBP52 regulate androgen receptor dimerization and proliferation in prostate cancer cells
Autor:
Keisuke Maeda, Makoto Habara, Mitsuyasu Kawaguchi, Hiroaki Matsumoto, Shunsuke Hanaki, Takahiro Masaki, Yuki Sato, Hideyasu Matsuyama, Kazuki Kunieda, Hidehiko Nakagawa, Midori Shimada
Publikováno v:
Molecular Oncology, Vol 16, Iss 4, Pp 940-956 (2022)
The growth of prostate cancer is dependent on the androgen receptor (AR), which serves as a ligand‐specific transcription factor. Although two immunophilins, FKBP51 and FKBP52, are known to regulate AR activity, the precise mechanism remains unclea
Externí odkaz:
https://doaj.org/article/f09ae7f5c53f4b779fe5929a3187c622
Autor:
Kosuke Shimizu, Ryo Inoue, Shinobu Tomochika, Naohito Isoyama, Yoshiaki Yamamoto, Hiroaki Matsumoto, Koji Shiraishi, Shigefumi Yoshino, Toyonori Tsuzuki, Hideyasu Matsuyama
Publikováno v:
IJU Case Reports, Vol 5, Iss 1, Pp 32-35 (2022)
Introduction Mucin‐producing adenocarcinoma of the prostate is a rare disease that includes prostate adenocarcinoma with mucus production, secondary adenocarcinoma from the bladder or colorectum, and adenocarcinoma from the urothelium of the prosta
Externí odkaz:
https://doaj.org/article/b2328171630e459cba46f8da891dafda
Autor:
Hideo Fukuhara, Takahiro Nohara, Koshiro Nishimoto, Yutaka Hatakeyama, Yuki Hyodo, Yoshiyasu Okuhara, Masafumi Oyama, Atsushi Mizokami, Keiji Inoue, Hideyasu Matsuyama, on behalf of the Japan Urological Photodynamic Society
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT). Meth
Externí odkaz:
https://doaj.org/article/b765102c94db4282a59ab0dcca0747cb
Autor:
Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama, Takeshi Seto, Shoko Tsukube, Kazuhiro Suzuki
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
Abstract Background The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m2 in Japan and Europe. Although lower doses are established alternatives based on randomized controlled trials, the safety and
Externí odkaz:
https://doaj.org/article/3826b0b23afb4eb6bc97b333eb8f5f06